Immune Checkpoint Blockade

GPTKB entity

Statements (49)
Predicate Object
gptkbp:instanceOf gptkb:immunotherapy
gptkb:Cancer_Immunotherapy
gptkbp:alternativeName Checkpoint inhibitor therapy
gptkbp:approvedBy gptkb:Head_and_neck_cancer
gptkb:Melanoma
gptkb:Renal_cell_carcinoma
gptkb:Bladder_cancer
gptkb:Gastric_cancer
gptkb:Non-small_cell_lung_cancer
Hodgkin lymphoma
Hepatocellular carcinoma
Triple-negative breast cancer
gptkbp:combines Chemotherapy
Radiotherapy
Targeted therapy
Other immunotherapies
gptkbp:contraindication gptkb:autoimmune_disease
gptkbp:discoveredBy gptkb:James_P._Allison
gptkb:Tasuku_Honjo
gptkbp:hasApprovedDrug gptkb:Ipilimumab
gptkb:Nivolumab
gptkb:Pembrolizumab
gptkbp:hasBiomarker gptkb:PD-L1_expression
Microsatellite instability
Tumor mutational burden
gptkbp:mechanismOfAction Blocks immune checkpoint proteins
Enhances T cell response
gptkbp:nobelPrizeCategory Physiology or Medicine
gptkbp:NobelPrizeYear 2018
gptkbp:regulates T cell activation
Antitumor immunity
Immune checkpoints
gptkbp:relatedTo T cell exhaustion
Adaptive immunity
Immune evasion
Tumor microenvironment
gptkbp:routeOfAdministration Intravenous
gptkbp:sideEffect Dermatitis
Colitis
Endocrinopathies
Immune-related adverse events
Pneumonitis
gptkbp:target gptkb:CTLA-4
gptkb:PD-1
PD-L1
gptkbp:usedFor Cancer Treatment
gptkbp:bfsParent gptkb:ICB
gptkbp:bfsLayer 7
https://www.w3.org/2000/01/rdf-schema#label Immune Checkpoint Blockade